ClinicalTrials.gg
CompletedNCT03778593Updated Feb 4, 2021

FOLFIRINOX for 2nd-line Treatment of BTC

A Phase 2 interventional study of 5-Fluorouracil and Leucovorin in Biliary Tract Cancer, sponsored by Dong-A University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by Dong-A University Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing fluorouracil in Biliary Tract Neoplasms — 4 open to participants now, 5 under way, 1 of them phase 3. Fluorouracil · Biliary Tract Neoplasms.

Enrollment
9th of 14
34 · median 38
Started
2019
with 3 others
Phase 2
10 of 14
3 open now
Registered
7th of 14
by date
Lead sponsor
1 of 14
Dong-A University Hospital

Among the 14 studies testing fluorouracil in Biliary Tract Neoplasms, this one is the 9th largest by enrollment, is one of 4 that started in 2019, is one of 10 in phase 2, and was the 7th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

4 of the 14 studies testing fluorouracil in Biliary Tract Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing fluorouracil in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

Biliary tract cancer (BTC) is rare in the West, but it is relatively high in Asia, including Korea. Currently used as the standard primary treatment in metastatic or locally advanced BTC is gemcitabine/platinum combination chemotherapy.There is no standard secondary chemotherapy recognized after the failure of the gemcitabine/platinum first line treatment. The investigators try to evaluate role of 5-FU, leucovorin, irinotecan, and oxaliplatin combination chemotherapy (FOLFIRINOX) for the patients who progressed after gemcitabine/cisplatin first line chemotherapy.

Read the detailed description

\<Biliary tract cancer> Biliary tract cancer (BTC) is a common term for malignant tumors that occur in gallbladder and bile duct, the path in which bile is released. According to the anatomical location, biliary tract cancer is divided into intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma is classified as perihilar cholangiocarcinoma and distal cholangiocarcinoma. Biliary tract cancer is rare in the West, but it is relatively high in Asia, including Korea. Biliary tract cancer occurs annually in Korea, accounting for about 5,600 cases, 2.4 percent of the total cancer, and ranks sixth in deaths from cancer. Biliary tract cancer is a type of cancer that is difficult to treat because most patients are diagnosed with progressive diseases that cannot be operated. Only about a quarter of patients are diagnosed with surgical-ready conditions as a treatment where full surgical operation can be expected to complete, but the five-year survival rate for operation is poor at 8-44% due to a high recurrence after surgery.

\<Metastatic or relapsed biliary tract cancer treatment> Chemotherapy is the main treatment in BTC, which is relapsed or metastatic status. 5- Fluorouracil (5-FU)-based treatment has been shown to improve the survival period for pancreatic and bile cancer patients compared to the optimal supportive care (5-FU/leucovorin ± etoposide 6.0 vs. 2.5 months, p \<0.01). Also, chemotherapy helped maintain the quality of life. The improvement in quality of life over a period of at least four months showed a significant difference compared to 10% in the group that received only optimal supportive care for 36% of the chemotherapy group. (p \< 0.01). Currently used as the standard primary treatment in metastatic or locally advanced BTC is gemcitabine/platinum combination chemotherapy. In a large phase III study, Gemcitabine/cisplatin significantly improved the median value of the progressive free survival (PFS) period from 5.0 months to 8.0 months, and the overall survival (OS) period from 8.1 months to 11.7 months, compared to the gemcitabine alone. If Cisplatin is not available, oxaliplatin can be considered as a merger with gemcitabine. The Gemcitabine/oxaliplatin regimen reported in the phase II and phase III studies PFS was 4.2-5.5 months, median for the OS period was 9.5-12.4 months.

\<Salvage treatment of biliary tract cancer> To date, there is no standard secondary chemotherapy recognized after the failure of the gemcitabine/platinum primary treatment. Since BTC usually occurs at an advanced age and shows a low frequency of occurrence in the West, there are practical limitations to conducting large-scale clinical research. So far, there is no large three-phase study proving the benefits of secondary chemotherapy after the failure of gemcitabine/platinum chemotherapy. Implementation of secondary chemotherapy in actual clinicians is known to vary from country to country, depending on the medical judgment of the responsible clinician. In a large-scale retrospective study by the Association des Gastro-Enterologies Oncology (AGEO) group in France, 32.5% of the patients were treated with second line therapy, and 75% of the patients were reported in Japan. A retrospective study and a two-phase study and systematic literature review suggest that there will be a benefit from the treatment if second line treatment is selected for patients whose general health is relatively well maintained. Results of single or combination therapy using drugs such as Irinotecan, oxaliplatin, 5-FU, S-1, and capecitabine were reported in phase II and retrospective studies, yielding an average of 3.2 months of PFS, 7.7% of mean response rate, and 7.2 months of OS.

The 5-FU/leucovorin/irinotecan (FOLFIRI) therapy, along with the capecitabine/irinotecan therapy, is reported as the most commonly used secondary chemotherapy in the AGEO group in France. A treatment strategy for continuous use of FOLFIRI as a secondary treatment after the failure of Gemcitabine/oxaliplatin showed the median value for OS period of 21.9 months, and the median value for the PFS period. The PFS and OS due to the FOLFIRI was found to be 3.2 months and 8.4 months, respectively. On the other hand, the FOLFOX therapy, which combines oxaliplatin with 5-FU, showed a response rate of 21.6 % when administered as a secondary treatment after the failure of gemcitabine/cisplatin, and a median PFS of 3.1 months. A phase III study is currently underway that compares the administration of FOLFOX as a secondary treatment with the optimum support. In Korea, there is a problem with the standard reimbursement for applying to drugs prescribed to cancer patients, and in particular, cancer drugs that can be used as secondary therapy in metastatic BTC patients are limited. There is a need to improve the prognosis of BTC patients by expanding the use of various drugs that have been proven through external clinical research.

\<5-FU, leucovorin, irinotecan, and oxaliplatin combination chemotherapy (FOLFIRINOX) regimen for other cancer of BTC> In a pre-clinical experiment, oxaliplatin and irinotecan have synergistic effects and are known to have relatively no overlap of toxic effects among, 5-FU, leucovorin, irinotecan, and oxaliplatin. The combination treatment of 5-FU/leukovorin/irinotecan/oxaliplatin (FOLFIRINOX) had a high therapeutic effect on progressive pancreatic cancer and colon cancer. In a phase III study comparing FOLFIRINOX and gemcitabine as a first line treatment in metastatic pancreatic cancer, the objective response rate (32 vs. 9%), PFS (6.4 vs. 3.3 months) and OS (11.1 vs. 6.8 months) were significantly higher in FOLFIRINOX. On the other hand, treatment-related toxicities, with a grade 3/4 of neutropenia (46 vs. 21%), febrile neutropenia (5.4 vs. 1.2%), thrombocytopenia (9.1 vs. 3.6%), sensory neuropathy (9 vs. 0%), vomiting (23 vs. 18%), and diarrhea (113 vs. 2%) were more common in FOLFIRINOX. In a phase III study comparing the 5-FU/leukovorin/irinotecan/oxaliplatin(FORFOXRI) and the 5-FU/leukovorin/irinotecan(FORFIRI) as a first line treatment in metastatic colorectal cancer, the FORFOXRI group was objective response (66 vs. 41 %), the PFS (9.8 vs. 6.9 months) and the OS (2.6 vs. 16.7 months) showed significant improvements. In pancreatic cancer, FOLFIRINOX was a treatment that was limited in patients with good general condition due to its high level of toxicity, including neutropenia, but the dose-reduction proved to be applied not only as a primary treatment but also as a secondary treatment. In a phase II study of pancreatic cancer patients in China, there was a 29% of grade 3/4 neutropenia were reported due to the treatment of modified FOLFIRINOX using oxaliplatin 68 mg/m2, irinotecan 135 mg/m2, and 5-FU injection of 2,400 mg/m2 for 46 hours, and there was no increase in mortality and febrile neutropenia. Other major grade 3 or higher toxicity levels showed improved safety profiles with thrombocytopenia (4.8%), anemia (8.1%), infection (4.8%), and elevated liver enzyme (14.5%).

\<Rationale of this trial>

As a 2nd line treatment for metastatic BTC the assessment of modified FOLFIRINOX is supported by:

  • The prognosis for metastatic BTC, which fails first line therapy, is poor and has no standardized treatment. Therefore, better treatment modalities are required to improve the survival of patients who no longer respond to first line treatment and to maintain the quality of life.
  • Treatments that use irinotecan or oxaliplatin as secondary therapy for metastatic BTC have been shown in retrospective and phase II studies and are actually used in clinical practice of other countries.
  • Oxaliplatin and irinotecan have synergistic effects and the FOLFIRINOX therapy, which uses both drugs together in 5-FU/leucovorin, has been shown to increase efficacy in pancreatic and colon cancer.
  • The modified FOLFIRINOX, which was used with reduced dosage, indicates an acceptable toxic profile while maintaining its efficacy
03

Conditions studied

  • Biliary Tract Cancer

Keywords

  • biliary tract carcinoma
  • 5-FU
  • Irinotecan
  • oxaliplatin
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed BTC (cholangiocarcinoma or gall bladder (GB) cancer) , except ampulla of Vater cancer
  2. In the event that the progression of the gemcitabine/cisplatin is experienced during or after discontinuation of the treatment for , locally advanced or (it may be considered as a first line treatment that recurrence within six months of completion of the or neo-adjuvant chemotherapy using gemcitabine/cisplatin)
  3. Patient (or legal representative) has completed an approved consent documents that he or she will participate in the test after receiving sufficient information about the clinical trial
  4. East clinical oncology group () performance status 0-1
  5. One or more by v1.1.
  6. Appropriate organ functions; A. Liver: ≤ 3 mg/dL, (AST) or alanine aminotransferase (ALT) ≤ 2.5 x (in cases of liver metastasis, AST or ALT ≤ 5 x ULN) B. Kidney: An estimate of creatine clearance rate according to the formula (or local institution's standard method) > 30 mili-liter (mL)/min C. ≥ 9 g/dL (transfusion allowed), (ANC) ≥ 1500/μL, count ≥ 75,000/μL.
  7. Expected life time over 3 months.
  8. Over 19 years old.
  9. In case of proper bile excretion function
  10. Have the will and ability to comply with the clinical trial plan during the study period, including treatment and scheduled visits and examination.
  11. For pre-menopausal women and for women less than one year after the onset of menopause, serum or urine pregnancy tests shall be confirmed negative during screening.
  12. For men and fertile women, the use of effective methods should be agreed (effective contraception should be used for at least 30 days prior to the initial administration of a drug, the trial period, and at least 90 days after the discontinuation of the test participation).

Exclusion criteria

Exclusion Criteria:

  1. ≥ 2 of prior chemotherapy for progressive BTC (except for /neo-adjuvant chemotherapy with resting of more than six months)
  2. Symptomatic or untreated or spinal cord compression .
  3. Previous treatment using Irinotecan or oxaliplatin
  4. In case of major surgery within four weeks just before registration, excluding for diagnosis
  5. In case of chemotherapy or radiation therapy was received within three weeks prior to the administration of a test medication
  6. Grade 2 or higher peripheral neuropathy
  7. Grade 2 or higher toxicities caused by a previous cancer treatment based on v 4.03 other than hair loss
  8. A person diagnosed with another malignant tumor within the last five years. Exceptions include basal or squamous cell carcinoma of the skin or intraepithelial neoplasia (bladder, uterine cervical, colorectal, breast)
  9. Pregnant or nursing woman
  10. If there is a severe or uncontrolled systemic disease, active infection, active bleeding tendency or organ transplantation history (including allo-hematopoietic stem cell transplantation)
  11. The following virus infection A. Known positive history for (Human Immunodeficiency virus, HIV) test or known acquired immunodeficiency syndrome (AIDS) B. virus (HBV) or virus (HCV) infection (positive Hepatitis B surface -Ag (+) or HCV RNA (+) if anti-HCV Ab screening test is positive)
  12. If there is a known alcohol or drug abuse
  13. In cases of (i.e., active) cardiovascular disease: cerebral hemorrhage/brain infarction, myocardial infarction (pre-registration \< 6 months), unstable angina, congestive heart failure ( classification ≥2) or arrhythmia needed drug therapy.
  14. In case of a mental state in which it is impossible to understand and provide the consent.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    mFOLFIRINOX

    D1 Oxaliplatin 65 mg/m2 + 5% dextrose water (5DW) 200 mL mix IV over 2 hours followed by, D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1 liter (1L) continuous IV over 23 hours repeat every 2 weeks

    Drug: 5-Fluorouracil · Drug: Leucovorin · Drug: Irinotecan · Drug: Oxaliplatin · Drug: 5% dextrose water

Interventions

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks

  • D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks

  • D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks

  • D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks

  • Drug5% dextrose water

    mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin

    Also known as: 5DW

06

What researchers measure

Primary outcomes

  1. Response rate of treated participants

    Rate of response including complete response and partial response by treatment. Response will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: up to 6 months

Secondary outcomes

  1. Progression free survival (PFS) duration of treated participants

    duration measure from treatment day to progression + death events. Calculated by Kaplan-Meier survival analysis.

    Time frame: up to 12 months

  2. Overall survival (OS) duration of treated participants

    duration measure from treatment day to death events. Calculated by Kaplan-Meier survival analysis.

    Time frame: up to 12 months

  3. Incidence of Treatment-Emergent Adverse Events of participants

    all adverse events during treatment. Evaluated with National Cancer Institute(NCI)-\] Common Terminology Criteria for Adverse Events (CTCAE) v4.03

    Time frame: up to 12 months

Other outcomes

  1. EORTC -QoL-C30

    Evaluate patients' life quality evaluation during treatment every 2 months with questionaires. European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (EORTC QOL-C30) will be used.

    Time frame: up to 12 months

07

Study locations

1 site
  • Dong-A University Hospital
    Busan, 49201, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Mar 2019, 0 months.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's 0 months is below that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2018
First posted
Dec 19, 2018
StartActual
Mar 1, 2019
Primary completionActual
Mar 1, 2019
CompletionActual
Jan 14, 2021
Last update
Feb 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03778593
Lead sponsor
Dong-A University Hospital
Responsible party
Sung Yong Oh (Associate Professor, Dong-A University Hospital) — Principal investigator
First posted
Dec 19, 2018
Start date
Mar 1, 2019
Primary completion
Mar 1, 2019
Completion
Jan 14, 2021
Last update
Feb 4, 2021

Study contacts

Sung Yong Oh, M.D.
principal investigator · Dong-A University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Leucovorin · Irinotecan · Oxaliplatin

Start the discussion